• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cabaletta Bio Inc (NQ: CABA )

    4.650 +0.450 (+10.71%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cabaletta Bio Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio to Participate in Upcoming Investor Conferences in September
    From Cabaletta Bio
    Via GlobeNewswire
    Recap: Cabaletta Bio Q4 Earnings
    Via Benzinga
    Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 12/8
    Via Investor Brand Network
    CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
    CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Cabaletta Bio
    Via GlobeNewswire
    Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
    CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
    Via Benzinga
    Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
    From Cabaletta Bio
    Via GlobeNewswire
    Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
    From Cabaletta Bio
    Via GlobeNewswire
    Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024
    CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    From Cabaletta Bio
    Via GlobeNewswire
    CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023
    CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
    From Cabaletta Bio
    Via GlobeNewswire
    Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
    On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding onto Regions Financial Corporation (NYSE: RF). 
    Via Benzinga
    Cabaletta Bio to Participate in Upcoming Investor Conferences in March
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Cabaletta Bio
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
    From Cabaletta Bio
    Via GlobeNewswire
    Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Cabaletta Bio
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.